What does this research mean for the field?

Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist offers complementary mechanisms that may provide superior renal protection and reduce the progression of chronic renal disease compared to monotherapy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To explore the effectiveness of ACE inhibitors and calcium antagonists in slowing renal disease progression.

January 1, 1996Renal Failure

Review

View Full Paper

Ask AI

Bookmark

Why the study?

Does combination therapy with an ACE inhibitor and a calcium antagonist retard the progression of chronic renal disease more effectively than monotherapy?

Population

Patients with chronic renal disease, including those with insulin-dependent diabetes mellitus, type II…

Comparison

Combination therapy with an… vs Monotherapy with either an ACE inhibitor or a…

Design

Review

Authors

MEMurray EpsteinUniversity of Miami

Discussion

Member takes

Implication

May support combined ACE inhibitor-calcium antagonist therapy in proteinuric CKD; hypothesis-generating and requires randomized confirmation before practice change.

Key Points

To explore the effectiveness of ACE inhibitors and calcium antagonists in slowing renal disease progression.
Reviewed long-term studies on ACE inhibitors and calcium antagonists in nondiabetic renal disease.
Initiated randomized prospective studies comparing combination therapy to monotherapy in antihypertensive treatment.
Analyzed effects on proteinuria and glomerular filtration rate (GFR) improvements.
Combination therapy significantly reduced proteinuria compared to monotherapy.
Patients receiving combination therapy experienced a slower decline in glomerular filtration rate (GFR) than those on monotherapy.
Achieved similar blood pressure reduction with enhanced renal protection using combined agents.

Structured PICO

Does combination therapy with an ACE inhibitor and a calcium antagonist retard the progression of chronic renal disease more effectively than monotherapy?

Population

Patients with chronic renal disease, including those with insulin-dependent diabetes mellitus (IDDM), type II diabetes, and nondiabetic renal disease

Intervention

Combination therapy with an angiotensin-converting enzyme (ACE) inhibitor and a calcium antagonist

Comparator

Monotherapy with either an ACE inhibitor or a calcium antagonist

Outcome

Progression of renal disease (reduction in proteinuria and rate of decline in glomerular filtration rate)surrogate

This review highlights the theoretical and emerging clinical evidence supporting the use of combined ACE inhibitor and calcium antagonist therapy for enhanced renal protection in chronic kidney disease.

Cite This Study

Murray Epstein (1996) studied this question.

synapsesocial.com/papers/6a1e8ac00a6b1b87af954d22 https://doi.org/10.3109/08860229609047709

Topics

Hypertension management

View Full Paper

Ask AI

Bookmark

Implication

May support combined ACE inhibitor-calcium antagonist therapy in proteinuric CKD; hypothesis-generating and requires randomized confirmation before practice change.

Review

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Review

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider